Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation

Authors

Stephen P Persaud, Washington University School of Medicine in St. Louis
Julie K Ritchey, Washington University School of Medicine in St. Louis
Sena Kim, Washington University School of Medicine in St. Louis
Sora Lim, Washington University School of Medicine in St. Louis
Peter G Ruminski, Washington University School of Medicine in St. Louis
Matthew L Cooper, Washington University School of Medicine in St. Louis
Michael P Rettig, Washington University School of Medicine in St. Louis
Jaebok Choi, Washington University School of Medicine in St. Louis
John F DiPersio, Washington University School of Medicine in St. Louis

Journal

Journal of clinical investigation

Publication Date

12-15-2021

Volume

131

Issue

24

First Page

e145501

Document Type

Open Access Publication

DOI

10.1172/JCI145501

Rights and Permissions

Ruminski PG, Cooper ML, Rettig MP, Choi J, DiPersio JF. Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2021 Dec 15;131(24):e145501. doi: 10.1172/JCI145501.

Recommended Citation

Persaud, Stephen P; Ritchey, Julie K; Kim, Sena; Lim, Sora; Ruminski, Peter G; Cooper, Matthew L; Rettig, Michael P; Choi, Jaebok; and DiPersio, John F, "Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation." Journal of clinical investigation. 131, 24. e145501 (2021).
https://digitalcommons.wustl.edu/open_access_pubs/11121